A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

NCT07754825 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: LT3001 Drug:high dose
DRUG: LT3001 Drug: low dose
DRUG: Placebo

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd